Takakura Yoshinobu, Takemoto Seiji, Nishikawa Makiya
Department of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan.
Curr Opin Mol Ther. 2007 Aug;9(4):385-91.
Hsp-based tumor vaccines, autologous tumor-derived Hsp-peptide complexes, have been applied to cancer immunotherapy for the treatment of cancer patients with a variety of advanced malignancies. Data from clinical trials, including those from phase III, have so far demonstrated that the immunization strategy can induce significant tumor-specific immune responses. Some improved clinical outcomes have also been observed but the clinical utility of this strategy awaits further investigations. In addition, preclinical studies have been conducted to design a variety of novel Hsp-based tumor vaccines with improved therapeutic potentials. These approaches include development of Hsp fusion proteins and genetic vaccines using plasmid DNA and adenoviruses. Successful cancer immunotherapy with Hsp-based tumor vaccines will depend on the results obtained from both clinical trials and preclinical studies.
基于热休克蛋白（Hsp）的肿瘤疫苗，即自体肿瘤来源的Hsp - 肽复合物，已应用于癌症免疫治疗，用于治疗患有各种晚期恶性肿瘤的癌症患者。包括III期试验在内的临床试验数据迄今为止表明，这种免疫策略可诱导显著的肿瘤特异性免疫反应。也观察到了一些改善的临床结果，但该策略的临床实用性有待进一步研究。此外，已经开展了临床前研究，以设计具有更高治疗潜力的各种新型基于Hsp的肿瘤疫苗。这些方法包括开发Hsp融合蛋白以及使用质粒DNA和腺病毒的基因疫苗。基于Hsp的肿瘤疫苗成功的癌症免疫治疗将取决于临床试验和临床前研究获得的结果。
